BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 16177283)

  • 1. Targeted therapies for esophageal cancer.
    Tew WP; Kelsen DP; Ilson DH
    Oncologist; 2005 Sep; 10(8):590-601. PubMed ID: 16177283
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted agents and esophageal cancer--the next step?
    Aklilu M; Ilson DH
    Semin Radiat Oncol; 2007 Jan; 17(1):62-9. PubMed ID: 17185199
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [New strategies in the treatment of esophageal cancer].
    Bidoli P; Aglione S; Toffolatti L; De Candis D; Bajetta E
    Minerva Chir; 2002 Dec; 57(6):717-31. PubMed ID: 12592216
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preoperative therapy in esophageal cancer.
    Ku GY; Ilson DH
    Clin Adv Hematol Oncol; 2008 May; 6(5):371-9. PubMed ID: 18516027
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel targets in gastric and esophageal cancer.
    Valverde CM; Macarulla T; Casado E; Ramos FJ; Martinelli E; Tabernero J
    Crit Rev Oncol Hematol; 2006 Aug; 59(2):128-38. PubMed ID: 16829119
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activation of growth factor receptors in esophageal cancer--implications for therapy.
    Ekman S; Bergqvist M; Heldin CH; Lennartsson J
    Oncologist; 2007 Oct; 12(10):1165-77. PubMed ID: 17962610
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Esophageal cancer: adjuvant therapy.
    Ku GY; Ilson DH
    Cancer J; 2007; 13(3):162-7. PubMed ID: 17620765
    [TBL] [Abstract][Full Text] [Related]  

  • 8. REG I expression predicts long-term survival among locally advanced thoracic squamous cell esophageal cancer patients treated with neoadjuvant chemoradiotherapy followed by esophagectomy.
    Motoyama S; Sugiyama T; Ueno Y; Okamoto H; Takasawa S; Nanjo H; Watanabe H; Maruyama K; Okuyama M; Ogawa J
    Ann Surg Oncol; 2006 Dec; 13(12):1724-31. PubMed ID: 17009160
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multimodality therapy for the curative treatment of cancer of the esophagus and gastroesophageal junction.
    Ku GY; Ilson DH
    Expert Rev Anticancer Ther; 2008 Dec; 8(12):1953-64. PubMed ID: 19046115
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trends in management and prognosis for esophageal cancer surgery: twenty-five years of experience at a single institution.
    Ruol A; Castoro C; Portale G; Cavallin F; Sileni VC; Cagol M; Alfieri R; Corti L; Boso C; Zaninotto G; Peracchia A; Ancona E
    Arch Surg; 2009 Mar; 144(3):247-54; discussion 254. PubMed ID: 19289664
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cancer of the gastroesophageal junction: combined modality therapy.
    Ilson DH
    Surg Oncol Clin N Am; 2006 Oct; 15(4):803-24. PubMed ID: 17030275
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Emerging drugs for esophageal cancer.
    Homs MY; Voest EE; Siersema PD
    Expert Opin Emerg Drugs; 2009 Jun; 14(2):329-39. PubMed ID: 19453287
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeted therapy for oesophageal cancer: an overview.
    Syrigos KN; Zalonis A; Kotteas E; Saif MW
    Cancer Metastasis Rev; 2008 Jun; 27(2):273-88. PubMed ID: 18224295
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Advanced gastric cancer (GC) and cancer of the gastro-oesophageal junction (GEJ): focus on targeted therapies.
    Cappetta A; Lonardi S; Pastorelli D; Bergamo F; Lombardi G; Zagonel V
    Crit Rev Oncol Hematol; 2012 Jan; 81(1):38-48. PubMed ID: 21256046
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel targets in esophageal and gastric cancer: beyond antiangiogenesis.
    Lee W; Patel JH; Lockhart AC
    Expert Opin Investig Drugs; 2009 Sep; 18(9):1351-64. PubMed ID: 19642951
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systemic treatment for advanced (stage IIIb/IV) non-small cell lung cancer: more treatment options; more things to consider. Introduction.
    Bunn PA; Thatcher N
    Oncologist; 2008; 13 Suppl 1():1-4. PubMed ID: 18263768
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The emerging role of vascular endothelial growth factor receptor tyrosine kinase inhibitors.
    Langer CJ; Natale RB
    Semin Oncol; 2005 Dec; 32(6 Suppl 10):S23-9. PubMed ID: 16459176
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pretreatment T3-4 stage is an adverse prognostic factor in patients with esophageal squamous cell carcinoma who achieve pathological complete response following preoperative chemoradiotherapy.
    Chao YK; Chan SC; Liu YH; Chen HW; Wan YL; Chang HK; Fan KH; Liu HP
    Ann Surg; 2009 Mar; 249(3):392-6. PubMed ID: 19247024
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinicopathologic features of superficial esophageal cancer: results of consecutive 100 patients.
    Tachibana M; Hirahara N; Kinugasa S; Yoshimura H
    Ann Surg Oncol; 2008 Jan; 15(1):104-16. PubMed ID: 17891442
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multidisciplinary approach to esophageal and gastric cancer.
    Quiros RM; Bui CL
    Surg Clin North Am; 2009 Feb; 89(1):79-96, viii. PubMed ID: 19186232
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.